Second-generation device more effective in capturing circulating tumor cells

October 12, 2010

A redesigned version of the CTC-Chip - a microchip-based device for capturing rare circulating tumor cells (CTCs) - appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells. Massachusetts General Hospital (MGH) researchers - including members of the team that developed the CTC-Chip - report the second-generation device in a Proceedings of the National Academy of Sciences paper that has been released online.

"The originally CTC-Chip worked wonderfully in a small-scale laboratory setting, but limitations arose when we attempted to increase production for larger clinical studies. The new device performs as well or better than the previous technology with several additional benefits," says Shannon Stott, PhD, of the MGH Center for Engineering in Medicine, co-lead author of the PNAS paper. "It also was able to capture something that had never been seen using either the CTC-chip or the most prevalent previous technology - small clusters of CTCs, the significance of which we need to study."

CTCs are living solid tumor cells found at extremely low levels in the bloodstream. Until the 2007 development of the CTC-chip by researchers from the MGH Cancer Center and the Center for Engineering in Medicine, it was not possible to get information from CTCs that would be useful for clinical decision making.

In the original device, patient blood samples are passed over a silicon chip covered with microscopic posts coated with an antibody that binds to most tumor cells. Not only did this design proved challenging to manufacture reliably and cost-effectively, but the smooth flow of blood around the microposts also limited the number of CTCs that came into contact with the antibody-covered surfaces. In their search to increase the capture of CTCs, the researchers found that passing samples through a chamber lined with a herringbone pattern of grooves - an approach developed elsewhere for quickly mixing independent streams of fluid - would generate a more chaotic flow that could significantly increase the number of captured cells.

The HB-Chip also can process larger-volume blood samples, increasing the ability to find rare CTCs. The microchip is mounted on a standard glass slide, which allows the use of standard pathology tests to identify cancer cells; and the device can be easily opened, giving access to CTCs for additional testing and growth in culture. Experiments comparing the HB-Chip to the CTC-chip found the new device captured more than 90 percent of cancer cells introduced into blood samples - a 25 percent improvement over the CTC-chip. Tests of samples from cancer patients found the redesigned device at least as effective as the original.

The HB-Chip also captured clusters of 4 to 12 CTCs from several patient samples but not from samples to which cancer cells had been added. No previous technology for capturing CTCs has ever found such clumps of tumor cells. "These clusters may have broken off from the original tumor, or they might represent proliferation of CTCs within the circulation," says Mehmet Toner, PhD, director of the BioMicroElectroMechanical Systems Resource Center in the MGH Center for Engineering in Medicine, the paper's senior author. "Further study of these clusters could provide valuable insight in the metastatic process."

Daniel Haber MD PhD, director of the MGH Cancer Center and a co-author of the study, says, "This new technology is a powerful platform that will enable increasingly sophisticated analyses of metastasis and support clinical research in targeted cancer therapies."

While the MGH has filed a patent for the HB-Chip, the research team will continue to develop the technology before potential licensing is explored. The study was supported by grants from Stand Up to Cancer, the Prostate Cancer Foundation, the National Institute for Biomedical Imaging and Bioengineering, the National Cancer Institute and the American Cancer Society, along with several additional funders.
-end-
Toner is the Benedict Professor of Surgery and Stott is a research fellow in Surgery at Harvard Medical School. Chia-Hsien Hsu, PhD, formerly of the MGH Center for Engineering in Medicine and now with the National Health Research Institutes of Taiwan, was co-lead author of the PNAS paper. Additional co-authors are Dina Tsukrov, Ajay Shah, George Korir, Frederick Floyd Jr., Daniel Irimia and Sunitha Nagrath, MGH Center for Engineering in Medicine; and Min Yu, David Miyamoto, Belinda Waltman, Michael Rothenberg, Malgorzata Smas, Anna Gilman, Jenna Lord, Daniel Winokur, Simeon Springer, Lecia Sequist, Richard Lee, Kurt Isselbacher and Shyamala Maheswaran, MGH Cancer Center.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $600 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Massachusetts General Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.